SeqOne acquires Congenica to create a global leader in AI-powered genomic medicine

SeqOne, a pioneer in AI-driven genomic
analysis, has entered into a definitive agreement to acquire Congenica,
the UK company spun out of the Wellcome Sanger Institute. The acquisition
creates the largest global ‘software pure player’ in the genomics space,
serving over 160 labs in more than 30 countries.

Since its founding in 2012, Congenica
has drawn on deep clinical expertise to support more than 25 private and public
laboratories worldwide, contributing to flagship initiatives such as the NHS
Genomics Laboratory Hubs, Genomics England, and the Hong Kong Genome Program.

SeqOne complements this legacy with its AI-powered genomic analysis platform,
delivering advanced decision-support tools that enable molecular laboratories
to generate faster, more accurate, and scalable insights across oncology, rare and
inherited diseases, and infectious diseases.

The acquisition brings together
SeqOne’s cutting-edge NGS (Next-Generation Sequencing) analysis capabilities
with Congenica’s trusted clinical decision support and interpretation services,
creating an integrated offering that transforms complex genomic data into
actionable insights, accelerating rare disease diagnoses and advancing
personalised cancer therapies.

Martin Dubuc, CEO of SeqOne, commented:

The rapid pace of
personalised medicine demands continuous investment in software innovation and
deep specialization. By integrating Congenica’s world-class team, we are
further enhancing our strong growth trajectory and ability to provide
market-leading software to customers, expert interpretation services, and
deepening our presence in the UK market – a global leader in clinical genomics
since the landmark 100,000 Genomes Project.

This development arrives at a pivotal moment in medicine.
With the cost of sequencing a human genome having dropped dramatically, the
challenge facing hospitals and laboratories worldwide is not data generation
but data interpretation. This “interpretation bottleneck” remains the greatest
obstacle to advancing personalised medicine, one that requires sophisticated
software to overcome.

Dr. Richard Scott, CEO at Genomics
England, said:  

Congenica
has been an instrumental partner to Genomics England, particularly in advancing
rare disease diagnosis through their robust platform for clinical whole genome
analysis. We look forward to continuing this important work with the combined
expertise of the SeqOne team to deliver benefits for patients.

The acquisition builds on a period of
strong momentum for SeqOne, which has doubled its revenue and expanded its
international footprint from three to more than 30 countries in just the past
year. It follows the successful acquisition of Life & Soft in April,
extending the company’s expertise into multi-omics and virology, and is further
reinforced by a €20 million funding round from leading venture capital firms.

Together, these milestones have
accelerated SeqOne’s strategy to consolidate a fragmented market and establish
the definitive software operating system for the clinical genomics revolution.
As the integration moves forward, SeqOne remains committed to ensuring
continuity of service and support for Congenica customers, who will now benefit
from a broader, unified product portfolio. The company will also maintain a
strong UK presence at the Wellcome Sanger Institute.

Dr Andy Richards CBE, Chairman of
Congenica, shared:

The
Board of Congenica is proud of the immense impact our technology has had on
healthcare since our inception. We support this combination with SeqOne,
believing their vision and resources are best positioned to carry that legacy
forward and ensure our innovative platform continues to thrive and serve
patients globally.

The deal terms will remain
undisclosed.